Email Alert RSS English | 中文
Advanced Search
et alRelationship between tumor mutational burden and efficacy of targeted therapies in patients with advanced nonsmall cell lung cancer[J]. Chin J Clin Med, 2019, 26(4): 538-542. DOI: 10.12025/j.issn.1008-6358.2019.20190157
Citation: et alRelationship between tumor mutational burden and efficacy of targeted therapies in patients with advanced nonsmall cell lung cancer[J]. Chin J Clin Med, 2019, 26(4): 538-542. DOI: 10.12025/j.issn.1008-6358.2019.20190157
shu

Relationship between tumor mutational burden and efficacy of targeted therapies in patients with advanced nonsmall cell lung cancer

More Information
  • Received Date: February 01, 2019
  • Revised Date: March 05, 2019
    Graphical Abstract
    • Abstract
  • Objective：To explore the relationship between tumor mutational burden (TMB) and efficacy of targeted therapies in patients with advanced nonsmall cell lung cancer (NSCLC).Methods：Between Jan. 2016 and Jan. 2018, fiftyone NSCLC patients receiving targeted therapy were enrolled in Zhongshan Hospital, Fudan University. TMB levels in tumor tissue samples from these patients were examined using targeted nextgeneration sequencing.Results：The median TMB level of NSCLC patients with driver mutations and receiving targeted therapy was 6.2 mutations/Mb, with TMB levels in smokers significantly higher than nonsmokers (P=0.046). All enrolled patients were divided into high TMB and moderate/low TMB groups. Survival analysis showed that patients with moderate/low TMB had longer progressionfree survival (PFS) compared with patients with high TMB (410 d vs 217 d, HR= 0.331, 95% CI 0.1650.665, P=0.001 2). Subgroup analysis showed that the median PFS was longer in the moderate/low TMB group than that in the high TMB group among the subgroups of gender, whether smoking, and TP53 gene mutation status. In the subgroups of adenocarcinoma who harbor epidermal growth factor receptor (EGFR) mutations, EGFR exon 19 deletion, and EGFR L858R, the median PFS was also longer in the moderate/low TMB group than that in the high TMB group (P＜0.05).Conclusions：For advanced NSCLC patients with driver mutations, the TMB level of tumor tissue is a predictor of the efficacy of targeted therapy. High TMB level suggests that PFS is shorter in patients receiving targeted therapy.
    • FullText(HTML)
    • References (15)
  • [1]
    Rosenberg J E, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial[J]. Lancet, 2016,387(10031):1909-1920.
    [2]
    Rizvi N A, Hellmann M D, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer[J]. Science, 2015,348(6230):124-128.
    [3]
    Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma[J]. N Engl J Med, 2014,371(23):2189-2199.
    [4]
    Hellmann M D, Callahan M K, Awad M M, et al. Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer[J]. Cancer Cell, 2018,33(5):853-861.
    [5]
    Hellmann M D, Ciuleanu T E, Pluzanski A, et al. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden[J]. N Engl J Med, 2018,378(22):2093-2104.
    [6]
    Gandara D R, Paul S M, Kowanetz M, et al. Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab[J]. Nat Med, 2018,24(9):1441-1448.
    [7]
    Forde P M, Chaft J E, Smith K N, et al. Neoadjuvant PD-1 Blockade in Resectable Lung Cancer[J]. N Engl J Med, 2018,378(21):1976-1986.
    [8]
    Carbone D P, Reck M, Paz-Ares L, et al. First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer[J]. N Engl J Med, 2017,376(25):2415-2426.
    [9]
    Carbone D P, Reck M, Paz-Ares L, et al. First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer[J]. N Engl J Med, 2017,376(25):2415-2426.
    [10]
    Offin M, Rizvi H, Tenet M, et al. Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers[J]. Clin Cancer Res, 2018. doi: 10.1158/1078-0432.
    [11]
    Grigoriu B, Berghmans T, Meert A P. Management of EGFR mutated nonsmall cell lung carcinoma patients[J]. Eur Respir J, 2015,45(4):1132-1141.
    [12]
    Solomon B J, Mok T, Kim D W, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer[J]. N Engl J Med, 2014,371(23):2167-2177.
    [13]
    Shaw A T, Kim D W, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer[J]. N Engl J Med, 2013,368(25):2385-2394.
    [14]
    Shaw A T, Ou S H, Bang Y J, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer[J]. N Engl J Med, 2014,371(21):1963-1971.
    [15]
    Reungwetwattana T, Ou S H. MET exon 14 deletion (METex14): finally, a frequent-enough actionable oncogenic driver mutation in non-small cell lung cancer to lead MET inhibitors out of "40 years of wilderness" and into a clear path of regulatory approval[J]. Transl Lung Cancer Res, 2015,4(6):820-824.
    • Related Articles

Catalog

    Get Citation
    PDF
    XML
    Article views (2307) PDF downloads (1006) Cited by()
    Turn off MathJax
    Article Contents
    Abstract
    References

    Links

    沪ICP备16009103号-3

    沪公网安备 31010402004907号

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return